BR112014002200A2 - tratamento de câncer de mama - Google Patents

tratamento de câncer de mama

Info

Publication number
BR112014002200A2
BR112014002200A2 BR112014002200A BR112014002200A BR112014002200A2 BR 112014002200 A2 BR112014002200 A2 BR 112014002200A2 BR 112014002200 A BR112014002200 A BR 112014002200A BR 112014002200 A BR112014002200 A BR 112014002200A BR 112014002200 A2 BR112014002200 A2 BR 112014002200A2
Authority
BR
Brazil
Prior art keywords
breast cancer
cancer treatment
treatment
breast
cancer
Prior art date
Application number
BR112014002200A
Other languages
English (en)
Portuguese (pt)
Inventor
A Protter Andrew
Cochrane Dawn
Richer Jennifer
Original Assignee
Medivation Prostate Therapeutics Inc
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014002200(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivation Prostate Therapeutics Inc, Univ Colorado Regents filed Critical Medivation Prostate Therapeutics Inc
Publication of BR112014002200A2 publication Critical patent/BR112014002200A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014002200A 2011-07-29 2012-07-27 tratamento de câncer de mama BR112014002200A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161513361P 2011-07-29 2011-07-29
PCT/US2012/048471 WO2013066440A1 (en) 2011-07-29 2012-07-27 Treatment of breast cancer

Publications (1)

Publication Number Publication Date
BR112014002200A2 true BR112014002200A2 (pt) 2017-03-07

Family

ID=48192564

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014002200A BR112014002200A2 (pt) 2011-07-29 2012-07-27 tratamento de câncer de mama

Country Status (18)

Country Link
US (4) US9517229B2 (cg-RX-API-DMAC7.html)
EP (4) EP2739153B1 (cg-RX-API-DMAC7.html)
JP (2) JP6158180B2 (cg-RX-API-DMAC7.html)
KR (1) KR101923250B1 (cg-RX-API-DMAC7.html)
CN (1) CN103997894B (cg-RX-API-DMAC7.html)
BR (1) BR112014002200A2 (cg-RX-API-DMAC7.html)
CA (1) CA2843417C (cg-RX-API-DMAC7.html)
CY (1) CY1121038T1 (cg-RX-API-DMAC7.html)
DK (1) DK2739153T3 (cg-RX-API-DMAC7.html)
EA (1) EA028452B1 (cg-RX-API-DMAC7.html)
ES (1) ES2696074T3 (cg-RX-API-DMAC7.html)
HU (1) HUE040524T2 (cg-RX-API-DMAC7.html)
MX (1) MX359664B (cg-RX-API-DMAC7.html)
PH (1) PH12014500248B1 (cg-RX-API-DMAC7.html)
PL (1) PL2739153T3 (cg-RX-API-DMAC7.html)
PT (1) PT2739153T (cg-RX-API-DMAC7.html)
SI (1) SI2739153T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013066440A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2739153B1 (en) * 2011-07-29 2018-08-22 Medivation Prostate Therapeutics LLC Treatment of breast cancer
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
LT3305285T (lt) 2012-09-26 2020-12-10 Aragon Pharmaceuticals, Inc. Anti-androgenai, skirti gydyti nametastazavusį kastracijai atsparų prostatos vėžį
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
US9937169B2 (en) * 2013-04-17 2018-04-10 Signal Pharmaceuticals, Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
AU2013404949B2 (en) * 2013-11-07 2018-10-18 Deciphera Pharmaceuticals, Llc Methods for inhibiting TIE2 kinase useful in the treatment of cancer
JP6945587B2 (ja) * 2013-11-07 2021-10-06 デシフェラ ファーマシューティカルズ，エルエルシー ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
EP3148336B1 (en) 2014-05-28 2019-10-02 Eisai R&D Management Co., Ltd. Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
MX2017007707A (es) 2014-12-12 2018-03-06 Medivation Prostate Therapeutics Llc Metodo para predecir respuesta a agentes terapeuticos de cancer de mama y metodo de tratamiento de cancer de mama.
WO2016141167A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Combination liposomal pharmaceutical formulations
US10736845B2 (en) 2015-03-03 2020-08-11 Cureport Inc. Dual loaded liposomal pharmaceutical formulations
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
US9963433B2 (en) * 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
KR102795129B1 (ko) 2017-06-22 2025-04-15 셀진 코포레이션 B형 간염 바이러스 감염을 특징으로 하는 간세포 암종의 치료
CA3079135A1 (en) 2017-10-16 2019-04-25 Arturo Molina Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN107987055A (zh) * 2017-12-19 2018-05-04 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
BR112020015581A2 (pt) 2018-01-31 2021-02-02 Deciphera Pharmaceuticals, Llc terapia de combinação para o tratamento de tumores estromais gastrointestinais
SG11202007287XA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of mastocytosis
WO2020113088A1 (en) * 2018-11-30 2020-06-04 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
KR20220045189A (ko) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양을 치료하는 방법
CN119950433A (zh) 2019-12-30 2025-05-09 德西费拉制药有限责任公司 非晶型激酶抑制剂制剂及其使用方法
PL4084779T3 (pl) 2019-12-30 2025-02-24 Deciphera Pharmaceuticals, Llc Kompozycje 1-(4-bromo-5-(1-etylo-7-(metyloamino)-2-okso-1,2-dihydro-1,6-naftyrydyn-3-ylo)-2-fluorofenylo)-3-fenylomocznika
EP4188330A4 (en) * 2020-08-03 2024-09-04 Oncocyte Corporation CLASSIFICATION OF TUMORS AND PREDICTION OF RESPONSE
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
KR101332924B1 (ko) * 2005-05-13 2013-11-26 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
EP1954708A4 (en) 2005-11-23 2009-05-13 Univ Utah Res Found Methods and compositions involving intrinsic genes
SI3412290T1 (sl) 2006-03-27 2021-09-30 The Regents Of The University Of California Modulator androgenih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenimi receptorji
CN102755318B (zh) 2006-03-29 2014-09-10 加利福尼亚大学董事会 二芳基硫代乙内酰脲化合物
PE20121470A1 (es) * 2007-10-26 2012-11-18 Univ California Compuestos de diarilhidantoina como antagonistas del receptor de androgeno
US8450290B2 (en) * 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
WO2009114534A1 (en) * 2008-03-14 2009-09-17 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
PL2297359T4 (pl) 2008-05-30 2014-07-31 Univ North Carolina Chapel Hill Profile ekspresji genów do przewidywania skutków raka piersi
JP2012518661A (ja) 2009-02-24 2012-08-16 メディベイション プロステイト セラピューティクス， インコーポレイテッド 特定のジアリールヒダントインおよびジアリールチオヒダントイン化合物
EP2416657A4 (en) 2009-04-09 2012-09-05 Medivation Prostate Therapeutics Inc COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF
US8507195B2 (en) * 2009-08-20 2013-08-13 The Regents Of The University Of Colorado MiRNAs dysregulated in triple-negative breast cancer
EP2485804A4 (en) 2009-10-07 2015-07-29 Medivation Technologies Inc SUBSTITUTED PHENYLCARBAMOYL ALKYLAMINOAREN COMPOUNDS AND N, N'-BIS-ARYL UREA COMPOUNDS
EP2685988A4 (en) 2011-03-15 2014-08-20 Univ North Carolina Methods of treating breast cancer with anthracycline therapy
EP2739153B1 (en) * 2011-07-29 2018-08-22 Medivation Prostate Therapeutics LLC Treatment of breast cancer
WO2013082440A2 (en) 2011-11-30 2013-06-06 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with taxane therapy
AU2013306380A1 (en) 2012-08-23 2015-03-05 The Regents Of The University Of Colorado, A Body Corporate Method for determining breast cancer treatment
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
US20140154681A1 (en) 2012-11-12 2014-06-05 Nanostring Technologies, Inc. Methods to Predict Breast Cancer Outcome
US10679730B2 (en) 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
MX2017007707A (es) 2014-12-12 2018-03-06 Medivation Prostate Therapeutics Llc Metodo para predecir respuesta a agentes terapeuticos de cancer de mama y metodo de tratamiento de cancer de mama.

Also Published As

Publication number Publication date
PT2739153T (pt) 2018-11-28
EP3430907A1 (en) 2019-01-23
CA2843417C (en) 2018-08-21
PH12014500248B1 (en) 2018-08-31
KR20140107174A (ko) 2014-09-04
CY1121038T1 (el) 2019-12-11
US20140296312A1 (en) 2014-10-02
JP2014524934A (ja) 2014-09-25
PL2739153T3 (pl) 2019-04-30
HUE040524T2 (hu) 2019-03-28
HK1201413A1 (en) 2015-09-04
WO2013066440A1 (en) 2013-05-10
US20170087132A1 (en) 2017-03-30
US9517229B2 (en) 2016-12-13
PH12014500248A1 (en) 2014-03-17
WO2013066440A9 (en) 2013-07-18
JP2017141269A (ja) 2017-08-17
EP3791724A1 (en) 2021-03-17
EP2739153B1 (en) 2018-08-22
JP6158180B2 (ja) 2017-07-05
ES2696074T3 (es) 2019-01-14
CN103997894B (zh) 2016-08-24
MX359664B (es) 2018-10-05
EA028452B1 (ru) 2017-11-30
KR101923250B1 (ko) 2018-11-28
CA2843417A1 (en) 2013-05-10
DK2739153T3 (en) 2018-12-03
EP3610731A1 (en) 2020-02-19
US10111861B2 (en) 2018-10-30
HK1198867A1 (en) 2015-06-19
EA201400178A1 (ru) 2014-11-28
CN103997894A (zh) 2014-08-20
SI2739153T1 (sl) 2018-12-31
EP2739153A4 (en) 2015-03-11
US20210069154A1 (en) 2021-03-11
EP2739153A1 (en) 2014-06-11
MX2014001218A (es) 2014-08-22
US20190262315A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
IL289300A (en) Combination therapy for treating cancer
BR112014002200A2 (pt) tratamento de câncer de mama
IL267242B (en) Cancer treatment
HUE047198T2 (hu) Fitokannabinoidok emlõrák kezelésére
BR112014007603A2 (pt) métodos de tratamento do câncer
LT2707030T (lt) Vėžio gydymas
PT2897620T (pt) Método de tratamento de cancro
HUE046667T2 (hu) Rák kombinatív kezelése
IL237558A0 (en) Methods for treating locally advanced breast cancer
BR112014005080A2 (pt) métodos para o tratamento de câncer de mama
PL3967315T3 (pl) Akkermansia muciniphila do leczenia nowotworu złośliwego
BR112014012880A2 (pt) tratamento imunogênico do câncer
HUE045314T2 (hu) Kombinációs terápia rák kezelésére
BR112013011659A2 (pt) métodos de tratamento do câncer
SMT201600235B (it) Predittori per il trattamento del cancro
EP2903644A4 (en) TREATMENT OF CANCER
IL254964A0 (en) A method for treating breast cancer
GB201217892D0 (en) Treatment of cancer
BR112012030907A2 (pt) bomba de mama
DK2872176T3 (en) Cancer treatment
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
GB201106630D0 (en) Cancer therapy
GB201222563D0 (en) Cancer treatment
GB201217890D0 (en) Treatment of cancer
BR112015008366A2 (pt) método de tratamento de câncer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 47/28 , A61K 31/17

Ipc: A61K 31/4184 (2006.01), A61K 31/4166 ¢...!

B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

B25G Requested change of headquarter approved

Owner name: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY COMPANY (US) ; MEDIVATION PROSTATE THERAPEUTICS LLC (US)